Background: Open surgical repair remains the "gold standard" treatment for chronic type B aortic dissection (cTBD) with aneurysm. Thoracic endovascular aortic repair (TEVAR) has gained popularity in recent years for the treatment of thoracic aortic diseases, including cTBD. We assessed the effectiveness of TEVAR in the treatment of cTBD using the Vascular Quality Initiative (VQI) database.
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Questions Society for Vascular Surgery Phone: 800-258-7188; education@vascularsociety.org patients for extension of the dissection. Follow-up was available for 43 patients at a median time of 239 days (IQR, 38-377 days). Median change in sac diameter was À0.2 cm (IQR, À0.5 to 0.1 cm). Sac shrinkage of 0.5 cm was noted in 12 (27.9%), with sac growth >0.5 cm in four (9.3%) patients. Extent of stent graft coverage did not affect sac shrinkage (P ¼ .65). Patients with aneurysms $5.5 cm compared with <5.5 cm were more likely to demonstrate shrinkage (À0.6 cm vs 0.0 cm; 95% confidence interval, 0.3-11.7; P ¼ .04).
Conclusions: TEVAR for cTBD may be performed with acceptable rates of morbidity and mortality. Changes in sac diameter in the midterm are promising. Long-term data are needed to determine whether this approach is durable. (J Vasc Surg 2018;67:1345-52.)
Traditionally, patients with aneurysmal degeneration of the aorta due to chronic type B aortic dissection (cTBD) have been repaired with an open surgical approach. 1 Despite recent improvements in outcomes of contemporary data sets, there remains a significant morbidity and mortality from open surgery. [2] [3] [4] During recent years, thoracic endovascular aortic repair (TEVAR) has emerged as a treatment option for a multitude of aortic diseases, including cTBD. The aims are to exclude entry tears, to induce thrombosis within the false lumen, to stimulate remodeling of the thoracic aorta, and to prevent aortic growth. [5] [6] [7] [8] In the setting of acute complicated type B aortic dissection, TEVAR has shown favorable outcomes for patients with malperfusion, rupture, chest pain, and aortic enlargement. [9] [10] [11] [12] The Investigation of Stent Grafts in Aortic Dissection trial with extended follow-up (INSTEAD-XL) demonstrated reduced aorta-related mortality in patients who underwent TEVAR compared with medical therapy for uncomplicated type B aortic dissection. 6 TEVAR resulted in a predictable regression of the false lumen and expansion of the true lumen. However, the role of TEVAR for complicated cTBD as defined by aortic enlargement, persistence of symptoms despite medical therapy, and rupture remains largely unknown. Concerns about the ability of this technique to decompress the false lumen and to expand the true lumen, given the thickened intimal flap and mature entry tears in the setting of cTBD, have been described. The long-term durability of stent grafts in this setting also remains largely unknown. [13] [14] [15] [16] Although acceptable perioperative outcomes have been achieved, there remains a paucity of data for TEVAR for complicated cTBD. The aim of this study was to provide short-term and midterm results of patients who underwent TEVAR for cTBD. Specifically, results of perioperative outcomes, secondary interventions, mortality, and change in aortic sac diameter are described.
METHODS
A retrospective cohort study was performed using the Vascular Quality Initiative (VQI) registry. This study was approved by the Institutional Review Board of Northwell Health , and the need for consent of individual patients was waived. Using the VQI registry, all patients who underwent TEVAR for thoracic aortic disease were identified. A total of 4713 patients were identified from July 2010 to November 2015. Of these, 125 repairs were performed for cTBD, as recorded in the VQI registry. The VQI defines chronic dissection as >30 days.
Characteristics of the patients, morphology of the aortic dissection, operative details, perioperative outcome, and reinterventions were obtained from the registry, which is recorded prospectively. Measurements of the maximum aortic diameter were recorded on preoperative computed tomography (CT) imaging. Zones of entry tear were recorded per the Society for Vascular Surgery reporting standards for TEVAR. 17 The same reporting measures were used to identify extent of aortic stent graft coverage. Subjects were then divided into two groups, depending on the extent of coverage. Group A included subjects with stent graft coverage extending to zone 4. Group B included those with coverage extending to zone 5 and distal. Successful device delivery was defined as deployment of the stent graft in the planned thoracic aorta. Technical success was defined as satisfactory closure of the primary entry tear, endograft deployment without type I or type III endoleak, and absence of conversion or death within 24 hours. Clinical success included the absence of death, type I or type III endoleak, aneurysm expansion, rupture, or conversion to open repair. Early and midterm outcomes were defined according to reporting criteria as within 30 days of the index procedure and from 30 days to 5 years after the intervention, respectively. Early mortality was defined as all-cause mortality occurring within 30 days from the reference TEVAR procedure, and late mortality was defined as death occurring after that period. Follow-up was obtained from the VQI registry. Where available, postoperative sac diameter was measured and change in sac diameter was recorded. Sac shrinkage was defined as a reduction in diameter of >0.5 cm; sac growth was defined as an increase in diameter of >0.5 cm.
The analysis of the association between stent group and absolute change in aortic diameter was performed, initially using univariable analyses to identify factors that were associated with stent group, which therefore could be confounders in the relationship between stent group and aortic change. In these analyses, the Fisher exact test was used for categorical factors and the Mann-Whitney test was used for continuous factors. A multivariable regression model was then used to assess the association between aortic diameter change and stent group while adjusting for potential confounders identified. The t-test was used to compare aortic diameter change between patients with aneurysms $5.5 cm and patients with aneurysms <5.5 cm. Unless otherwise specified, a result was considered statistically significant at the P < .05 level of significance. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Of the 125 subjects with cTBD, median age was 65.0 years (interquartile range [IQR], 56.0-72.0 years), and 85 (68.0%) were male. Demographics of the patients and prior aortic interventions are summarized in Table I . Anatomic characteristics of the aneurysms are delineated in Table II . Median aneurysm diameter was 5.5 cm (IQR, 4.8-6.3 cm). Sixty-two (49.6%) subjects were asymptomatic on presentation, 57 (45.6%) were symptomatic, and six (4.8%) presented with rupture. Indication for TEVAR was pain in 53 (42.4%) subjects, refractory hypertension in 12 (9.6%), malperfusion in 5 (4.0%), rapid expansion in 16 (12.8%), aneurysm in 79 (63.2%), rupture in 8 (6.4%), and uncomplicated in 11 (8.8%) subjects.
Perioperative details are summarized in Table III . Median length of stay was 8.0 days (IQR, 4.0-11.0 days). The distal landing zone was aortic zone 4 in 27 (21.6%) and aortic zone 5 and distal in 98 (78.4%) subjects. Successful device delivery occurred in 123 (98%) subjects. Conversion to open repair occurred in one (0.8%) subject. A type IA endoleak was present in 2 (1.6%), type IB endoleak in 2 (1.6%) and type II endoleak in 2 (1.6%) subjects on completion of the procedure. Technical success was achieved in 121 (96.8%) subjects.
Perioperative complications are shown in Table IV . Inhospital mortality occurred in three (2.4%) subjects at 2 days, 9 days, and 16 days postoperatively. One death was secondary to a malperfusion complication, one was related to a complication of the aortic dissection, and the third was due to an unrelated event. Inhospital reintervention was required in 13 (10.4%) subjects at a median time of 7 days (IQR, 0.8-9.0 days). Indications included aortic enlargement in 1 (0.8%) subject and persistent false lumen perfusion in 2 (2.4%), extension of dissection in 2 (2.4%), and a type IA endoleak in 2 (2.4%) subjects. Three (2.4%) reinterventions were unrelated to the index procedure. Early clinical success was achieved in 113 (90.4%) subjects.
Follow-up was available for 43 (34.4%) subjects at a median time of 239 days (IQR, 38-377 days). This included 10 (23.2%) subjects from group A and 33 (76.7%) subjects from group B. There were no new occurrences of spinal cord ischemia, intestinal ischemia, or lower limb ischemia. There were no ruptures seen during follow up. There were five (11.6%) deaths, occurring at a median time of 93 days (IQR, 52-336 days) after the procedure. One death was due to a complication of the aortic dissection, three were from unrelated causes, and the other remains unknown. On follow-up CT imaging, the incidence of type IA endoleaks was 0 (0.0%). There was one (2.3%) type IB endoleak and one (2.3%) type II endoleak. There were two (4.7%) reinterventions required beyond 30 days; one endovascular intervention was performed at 384 days after the index procedure for a type II endoleak, and the second reintervention was performed for an unrelated disease. Median change in sac diameter was À0.2 cm (IQR, À0.5 to 0.1 cm). Sac shrinkage of >0.5 cm was noted in 12 (28%), with sac growth >0.5 cm in 4 (9%) subjects.
Univariable analyses showed that group A and group B did not significantly differ in terms of age (P ¼ .74), body mass index (P ¼ .60), preoperative maximum aorta diameter (P ¼ .59), stroke (P ¼ .62), coronary artery disease (P ¼ .62), congestive heart failure (P ¼ 1.00), chronic obstructive pulmonary disease (P ¼ .57), or diabetes (P ¼ 1.00). Duration of follow-up was significantly shorter for group A compared with group B (44.0 days vs 336.5 days; P ¼ .02). In the multivariable model, after adjusting for a possible confounding effect of duration of follow-up, the extent of stent graft coverage (group A vs group B) was not found to be significantly associated with sac shrinkage (P ¼ .65). In the sample, sac shrinkage was 1.7 mm in group A and 3.4 mm in group B. Patients with aneurysms $5.5 cm compared with <5.5 cm were more likely to demonstrate shrinkage (À0.6 cm vs 0.0 cm; 95% confidence interval, 0.3-11.7; P ¼ .04). Midterm clinical success was seen in 35 (81.4%) subjects.
DISCUSSION
TEVAR for cTBD has acceptable perioperative morbidity and mortality. Our series, which is one of the largest to date, confirms the work of others and shows that TEVAR is an acceptable treatment option for cTBD. Our finding of a 2.4% mortality is in keeping with previous series in The early reintervention rate of 10.4% in this study is slightly lower than what has been demonstrated by others, which is reported in the range of 15% to 22%. 14, 18, 26 In one of the largest existing series to date, Mani et al 21 demonstrated a reintervention rate in approximately one-third of patients treated with TEVAR for cTBD. Half of these reinterventions occurred after the first year, highlighting the need for prolonged follow-up. It is likely that the lower reintervention rate in our study is due to lack of follow-up. A well-recognized complication of TEVAR for cTBD is retrograde type A aortic dissection. This is related to the inherent fragility of the aortic wall. Extension of dissection occurred in two (1.6%) subjects in our series, which is in the range of 1.2% to 5.6% that has been reported by others. 26, [28] [29] [30] Proximal bare stents, metallic barbs, and balloon dilation of the stent graft have been associated with an increased risk of retrograde type A dissection. 18 In the patients in our series who experienced extension of the dissection, both had devices with no proximal bare stents. As this is a data registry, the use of balloon dilation of the stent graft remains unknown. Achieving a successful midterm outcome after TEVAR for cTBD has been shown to be difficult in prior studies. Full exclusion of the false lumen remains the challenge but is achieved in less than half of patients in the current literature. 15, 19, 20 The thick intimal flap of a chronic dissection, with multiple entry tears, results in increased difficulty in achieving thrombosis within the false lumen. 30 The absence of contrast enhancement in the false lumen on CT imaging can act as a surrogate marker of successful treatment. 31 Thrombosis of the false lumen is generally used as a measure of success after TEVAR for cTBD. Partial thrombosis has been shown to be associated with a poor outcome and may predict late aortic events. 32, 33 Persistent patency of the false lumen has also been shown to be a predictor of a negative outcome after TEVAR for cTBD. 31 Mani et al 21 demonstrated that lack of false lumen enhancement on arterial-phase CT due to reduced false lumen flow results in aortic diameter reduction, which can be used as a surrogate marker for a successful outcome. False lumen patency was unfortunately not routinely recorded in the VQI database, and as such, we are unable to compare our outcomes with existing data in this regard. Various methods have been used to categorize aortic remodeling after TEVAR for cTBD. These include false-true lumen ratios, volumetry, and diameter changes. 26, 34, 35 In our study using the VQI database, false lumen thrombosis, volumetry, and true and false lumen diameters as a variable were not available. As such, we used overall diameter changes. Sac shrinkage of >0.5 cm was seen in 28% of patients, and this should be seen as a surrogate marker of success. Sac growth >0.5 cm in 9% of subjects is seen as a treatment failure. Survival after TEVAR for cTBD has been shown to be lower where no aortic remodeling occurs, and this is also true in patients with stable aortic diameter. 21 The prognosis of the remaining patients in whom a change in diameter of <0.5 cm was noted remains to be determined. This group of patients may warrant closer follow-up and may subsequently need further interventions. The optimal timing of such remains unknown. The extent of stent graft required for cTBD remains controversial. Coverage of the primary entry tear alone has been shown to reduce false lumen pressure to essentially zero, with retrograde pressurization by distal entry tears seen as insignificant. 18, 36 Others have suggested that long length of aortic coverage is required in cTBD because of the limited ability of the aorta to remodel. 15, 30 In our series, we have shown no difference in sac behavior with aortic coverage extending to either zone 4 or zone 5 and distally. This may suggest that extensive aortic coverage offers no benefit in inducing false lumen thrombosis and aortic remodeling in cTBD. However, more robust follow-up with larger numbers of patients is needed to confirm this finding.
ARTICLE HIGHLIGHTS
No branched or fenestrated devices were used in our cohort of patients. A study by Oikonomou et al 37 reviewed outcomes of fenestrated and branched endografting in postdissection thoracoabdominal aortic aneurysms. In their study, technical success was 93.5% with a 30-day mortality of 9.6%. Given the greater extent of aneurysm and higher technical challenge of the procedure, it is not surprising that outcomes are somewhat worse than in our study. As such, our results are not generalizable for branched and fenestrated devices.
The optimal timing of TEVAR for type B aortic dissections remains unclear. TEVAR within 1 month after the index dissection has been shown to be inferior to optimal medical management, with a higher all-cause death and aorta-specific mortality. 38 TEVAR within 3 months has been shown to have more favorable aortic remodeling. 39 Fanelli et al confirmed the results of others and found a higher capacity of remodeling of acute rather than of chronic dissection after TEVAR, along with a lower false lumen thrombosis rate in chronic compared with acute dissection. [40] [41] [42] Whereas the ability of the aorta to remodel appears greater in the early months after the index dissection, the chronically dissected aorta still has the capacity to demonstrate shrinkage and morphologic changes. Improvements in morbidity and mortality in comparison to open surgical controls in this cohort further emphasize the appropriateness of this treatment for cTBD. Although there remains a paucity of evidence of midterm and long-term outcomes, it would appear that TEVAR for cTBD is an appropriate treatment option. This report has several important limitations. It is a retrospective review of a prospectively maintained database, without an open surgical cohort for comparison. The modest number of events and duration of follow-up has the potential to lead to a type II error. Indeed, the poor follow up, a well-recognized problem of most data registry sets, is a major limitation of this paper. However, given the low number of TEVARs performed for cTBD at individual centers, multicenter national registry sets such as the VQI are our only insight in providing large numbers of patients to assess outcomes. This is a multicenter study, and as such, there are no standardized criteria for selection of patients, treatment algorithm, or follow-up protocol. Heterogeneity in case selection and unreported surgical turndown rates further complicate the analysis. The role of TEVAR for cTBD is undefined, and there remains a lack of consensus about definitions of clinical success and treatment failure. Consensus reporting criteria are required to define endoleaks in TEVAR for cTBD, for example, how to clarify a type IB endoleak vs false lumen perfusion. Given the large number of centers involved in the VQI, it is unclear whether those involved in data entry have the same criteria to distinguish such terms. Certain data points that would have strengthened the analyses were also missing from the database, including the precise age of dissection at the time of treatment. Also, a wide range of stent grafts were used during the study period. This study was further limited by a lack of midterm and long-term follow up. The loss of follow-up affects the ability to perform an accurate analysis on patient outcomes.
CONCLUSIONS
TEVAR for cTBD has acceptable rates of perioperative morbidity and mortality. Changes in sac diameter in the short term and midterm are promising. The extent of aortic coverage appears to not affect aortic diameter changes. Robust midterm and long-term data are needed to determine whether this approach is durable.
